PROMISE
PROMISE was launched in November 2021 and will end in April 2024. It is led by the University of Edinburgh (UEDIN), the University Medical Centre Utrecht (UMCU) and the pharmaceutical company Sanofi.
The initiative built on RESCEU (Respiratory Syncytial Virus Consortium in Europe), another IMI project which generated valuable insights into the impact of RSV on healthcare systems and society, amongst other significant results, such as creating a biorepository to assist future research. PROMISE (Preparing for RSV Immunisation and Surveillance in Europe) brought together translational scientists, clinicians, public health agencies, the pharmaceutical industry, patient groups and clinical societies from 22 world class organisations to make a breakthrough in RSV (Respiratory Syncytial Virus) research. Funded by the Innovative Medicines Initiative (IMI), this initiative focused on advancing scientific knowledge on RSV to inform public health strategies and bolster the development and introduction of novel immunisations tools and therapeutics in Europe. Since the development of preventative measures such as a vaccine and monoclonal antibodies are well under way, PROMISE aims to prepare for the introduction of such treatments and prophylactic interventions.
Project ID
Start date: 1 november 2021
End date: 30 april 2024
Call: IMI2 – CALL 22
Type of action: Research and innovation action (RIA)
Grant agreement number: 101034339
Project coordinator: The University of Edinburgh and University Medical Centre Utrecht
Project leader: Sanofi
Contributions
Total Costs: 7.024.387 €
IMI Funding: 3.744.375 €
EFPIA in kind: 3.280.012 €
